- Home
- ELAB vs RDHL Comparison
ELAB vs RDHL Comparison
Compare ELAB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- RDHL
- Stock Information
- Founded
- ELAB 2020
- RDHL 2009
- Country
- ELAB United States
- RDHL Israel
- Employees
- ELAB N/A
- RDHL N/A
- Industry
- ELAB
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- RDHL Health Care
- Exchange
- ELAB Nasdaq
- RDHL Nasdaq
- Market Cap
- ELAB 6.6M
- RDHL 6.8M
- IPO Year
- ELAB 2023
- RDHL N/A
- Fundamental
- Price
- ELAB $4.55
- RDHL $2.45
- Analyst Decision
- ELAB
- RDHL
- Analyst Count
- ELAB 0
- RDHL 0
- Target Price
- ELAB N/A
- RDHL N/A
- AVG Volume (30 Days)
- ELAB 418.9K
- RDHL 121.9K
- Earning Date
- ELAB 05-14-2025
- RDHL 04-11-2025
- Dividend Yield
- ELAB N/A
- RDHL N/A
- EPS Growth
- ELAB N/A
- RDHL N/A
- EPS
- ELAB N/A
- RDHL N/A
- Revenue
- ELAB N/A
- RDHL $3,707,000.00
- Revenue This Year
- ELAB N/A
- RDHL $224.90
- Revenue Next Year
- ELAB N/A
- RDHL $82.69
- P/E Ratio
- ELAB N/A
- RDHL N/A
- Revenue Growth
- ELAB N/A
- RDHL N/A
- 52 Week Low
- ELAB $3.88
- RDHL $2.40
- 52 Week High
- ELAB $1,064.00
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- ELAB 35.23
- RDHL 26.68
- Support Level
- ELAB $4.08
- RDHL $2.64
- Resistance Level
- ELAB $5.07
- RDHL $2.90
- Average True Range (ATR)
- ELAB 0.86
- RDHL 0.23
- MACD
- ELAB 0.26
- RDHL 0.07
- Stochastic Oscillator
- ELAB 14.62
- RDHL 6.76
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.